Dawei Sun
8 Papers
1 Citations
Dawei Sun is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 5 publications.
Chat about Author
Papers
Potential epigenetic molecular regulatory networks in ocular neovascularization
Qiang Hu,Xue Heng Zhang,M. Sun,Bo Jiang,Zhongyu Zhang,Dawei Sun +5 more
TL;DR: This review focuses on recent advances in the epigenetic control of ocular neovascularization as well as discusses these new mechanisms.
Correction to: The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens
Bo Jiang,Lin Gao,Su Dong,Qingxue Hou,M. Sun,Jingjie Zhang,Haotian Yu,Zhongyu Zhang,Dawei Sun +8 more
TL;DR: The treat and extend (T&E) regimen can better maintain the stability of the treatment effect seen in patients with nAMD and the COVID-19 pandemic, and the T&E regimen should be a more advanced treatment option in the clinic.
2
Abstract 183: A novel bispecific antibody macrophage engager (BiME) designed for the treatment of solid tumors
Dawei Sun,Yanan Geng,Yue Wu,Rui Gao,Yefeng Lu,Quan Qiu,Yanfen Hu,Yingchao Liu,Xiaoli Guo,Xiaofeng Niu,Hongtao Lu +10 more
TL;DR: A novel bispecific antibody macrophage engager (BiME) designed for the treatment of solid tumors has been developed. BiME activates both myeloid and T cells to kill tumor cells and exhibits strong antitumor efficacy in mouse syngeneic tumor models.
1
1211 Dual targeting of innate and adaptive immune checkpoints with a PD-L1/SIRPα bispecific macrophage engager to promote anti-tumor activity
Dawei Sun,Hongtao Lu,Haixia Jiang,Yanan Geng,Jiahui Hu,Ziqiao Ding,Jinfeng Zhao,Xiang Xu,Wenqiang Lu,Xiaofeng Niu,Rui Gao,Zhihao Wu,Quan Qiu,Zheng Song,Yangsheng Qiu +14 more
- 01 Nov 2022
TL;DR: In this article , a bispecific antibody bound to PD-L1 expressing tumor cell and macrophage simultaneously, effectively inhibited CD47-SIRP a signal and triggered strong macophage phagocytosis.
793 Treatment of anti-SIRPα in combination with anti-TAA exerts superior anti-tumor activity
Xiaofeng Niu,Chunnian Wang,Jinfeng Zhao,Haiying Wang,Li Zhang,Jiahui Hu,Jingfeng Yu,Yefeng Lu,Xiaoli Guo,Haixia Jiang,R. Gao,Zhihao Wu,Yangsheng Qiu,Quan Qiu,Zheng Song,Dawei Sun,Hongtao Lu +16 more
- 01 Nov 2022
TL;DR: In this paper , ES004-B5 has been used in combination with anti-SIRP-a mAb in cancer treatment and showed promising results in a syngeneic mouse tumor model.